Results 211 to 220 of about 23,087 (229)

Bone Mineral Density After Transitioning From Denosumab to Alendronate

Journal of Clinical Endocrinology and Metabolism, 2020
David Kendler, Patricia Clark, Peter Ebeling   +2 more
exaly  

Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?

European Journal of Cancer, 2017
Emanuela Palmerini, N S Chawla, S P Chawla   +2 more
exaly  

Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS

Bone, 2017
M Carola Zillikens, Richard Eastell, Stuart H Ralston   +2 more
exaly  

Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies

Journal of Bone and Mineral Research, 2010
Ian Reid, David Kendler, David Dempster   +2 more
exaly  

Denosumab

Reactions Weekly, 2017
openaire   +1 more source

Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD

Journal of Bone and Mineral Research, 2007
Michael McClung, E Michael Lewiecki
exaly  

Denosumab

Reactions Weekly, 2013
openaire   +1 more source

Identification of the Risk Factors Associated with Hypocalcemia Induced by Denosumab

Biological and Pharmaceutical Bulletin, 2013
Masahiro Abe, Naoto Okada, Kazuyoshi Kawazoe   +2 more
exaly  

Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial

Journal of Bone and Mineral Research, 2013
Jacques P Brown
exaly  

Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics

European Journal of Cancer, 2016
Miguel Martin, D H Henry, M R Smith
exaly